Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide.

Angona A, Bellosillo B, Alvarez-Larrán A, Martínez-Avilés L, Camacho L, Pairet S, Fernández-Rodriguez MC, Ancochea A, Besses C.

Leuk Res. 2013 Aug;37(8):917-21. doi: 10.1016/j.leukres.2013.03.013. Epub 2013 Apr 15.

PMID:
23597578
[PubMed - indexed for MEDLINE]
2.

Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.

Besses C, Alvarez-Larrán A, Martínez-Avilés L, Mojal S, Longarón R, Salar A, Florensa L, Serrano S, Bellosillo B.

Br J Haematol. 2011 Feb;152(4):413-9. doi: 10.1111/j.1365-2141.2010.08467.x. Epub 2011 Jan 10.

PMID:
21219298
[PubMed - indexed for MEDLINE]
3.

Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.

Alvarez-Larrán A, Angona A, Martínez-Avilés L, Bellosillo B, Besses C.

Leuk Res. 2012 Mar;36(3):324-6. doi: 10.1016/j.leukres.2011.09.029. Epub 2011 Oct 15.

PMID:
22001278
[PubMed - indexed for MEDLINE]
4.

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.

Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD, Duval A, Maynadié M, Hermouet S.

Haematologica. 2008 Nov;93(11):1723-7. doi: 10.3324/haematol.13081. Epub 2008 Aug 25. Erratum in: Haematologica. 2010 Feb;95(2):344. Vidal, Aurélie [corrected to Duval, Aurélie].

PMID:
18728027
[PubMed - indexed for MEDLINE]
Free Article
5.

Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.

Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A.

Exp Hematol. 2013 Jul;41(7):627-34. doi: 10.1016/j.exphem.2013.03.007. Epub 2013 Mar 28.

PMID:
23542632
[PubMed - indexed for MEDLINE]
6.

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.

Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, Ponziani V, Bartalucci N, Tozzi L, Bosi A, Rambaldi A, Barbui T, Vannucchi AM.

Haematologica. 2010 Aug;95(8):1435-8. doi: 10.3324/haematol.2009.021444. Epub 2010 Apr 23. No abstract available.

PMID:
20418246
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
[PubMed - indexed for MEDLINE]
8.

Genotype-phenotype interactions in the myeloproliferative neoplasms.

Godfrey AL, Green AR.

Hematol Oncol Clin North Am. 2012 Oct;26(5):993-1015. doi: 10.1016/j.hoc.2012.07.003. Epub 2012 Aug 28. Review.

PMID:
23009934
[PubMed - indexed for MEDLINE]
9.

Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.

Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, Gorukmez O, Ocakoglu G.

Mol Biol Rep. 2012 Sep;39(9):8663-7. doi: 10.1007/s11033-012-1721-x. Epub 2012 Jun 22.

PMID:
22722988
[PubMed - indexed for MEDLINE]
10.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
[PubMed - indexed for MEDLINE]
Free Article
11.

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms.

Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K, Percy MJ, McMullin MF, Scott LM, Tapper W, Silver RT, Oscier D, Harrison CN, Grallert H, Kisialiou A, Strike P, Chase AJ, Green AR, Cross NC.

Blood. 2010 Jun 3;115(22):4517-23. doi: 10.1182/blood-2009-08-236448. Epub 2010 Mar 19.

PMID:
20304805
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.

PMID:
18496562
[PubMed - indexed for MEDLINE]
13.

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.

Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A.

Blood. 2008 Mar 1;111(5):2785-9. Epub 2007 Nov 15.

PMID:
18006699
[PubMed - indexed for MEDLINE]
Free Article
14.

Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.

Albizua E, Gallardo M, Barrio S, Rapado I, Jimenez A, Ayala R, Rueda D, Sanchez-Espiridion B, Puigdecanet E, Espinet B, Florensa L, Besses C, Martinez-Lopez J.

Ann Hematol. 2011 Aug;90(8):939-46. doi: 10.1007/s00277-011-1179-2. Epub 2011 Feb 18.

PMID:
21331593
[PubMed - indexed for MEDLINE]
15.

Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.

Martínez-Trillos A, Maffioli M, Colomer D, Alvarez-Larrán A, Pereira A, Angona A, Bellosillo B, Cervantes F.

Ann Hematol. 2014 May;93(5):797-802. doi: 10.1007/s00277-013-1989-5. Epub 2013 Dec 15.

PMID:
24337516
[PubMed - indexed for MEDLINE]
16.

The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.

Zhang X, Hu T, Wu Z, Kang Z, Liu W, Guan M.

Int J Hematol. 2012 Nov;96(5):611-6. doi: 10.1007/s12185-012-1169-8. Epub 2012 Sep 29.

PMID:
23054641
[PubMed - indexed for MEDLINE]
17.

Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.

Ho CL, Wu YY, Hung HM, Chang PY, Kao WY, Chen YC, Chao TY.

J Formos Med Assoc. 2012 Jan;111(1):34-40. doi: 10.1016/j.jfma.2012.01.003. Epub 2012 Feb 1.

PMID:
22333011
[PubMed - indexed for MEDLINE]
18.

Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.

Zalcberg IR, Ayres-Silva J, de Azevedo AM, Solza C, Daumas A, Bonamino M.

Haematologica. 2011 Mar;96(3):e18-20. doi: 10.3324/haematol.2010.037846. No abstract available.

PMID:
21357711
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

[Research progress on molecular pathogenesis of myeloproliferative neoplasms].

Liu L, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):239-43. Review. Chinese.

PMID:
21362261
[PubMed - indexed for MEDLINE]
20.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

PMID:
22251709
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk